Advent International holds 62,493,676 DH shares (NYSE: DH)
Advent International entities have reported beneficial ownership of 62,493,676 shares of Definitive Healthcare Corp.'s Class A common stock, representing 59.82% of the outstanding shares as of February 23, 2026. This ownership, detailed in a joint Schedule 13G/A filing, indicates shared voting and dispositive power among various Advent funds and related entities. The filing clarifies the control relationships and specific holdings of the Advent group, with the reported percentage based on 104,472,371 Class A shares outstanding.
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Elanco Animal Health (ELAN) and Align Tech (ALGN)
This article summarizes analyst ratings for three healthcare companies: Definitive Healthcare Corp (DH), Elanco Animal Health (ELAN), and Align Tech (ALGN). Definitive Healthcare received a Hold rating from Canaccord Genuity, while Elanco Animal Health received a Buy rating from Evercore ISI, and Align Tech also secured a Buy rating from Evercore ISI. The report includes price targets and analyst consensus for each stock, highlighting potential upsides.
Definitive Healthcare (DH) Posts US$9.3 Million Q4 Loss Testing Profit Turnaround Hopes
Definitive Healthcare (DH) reported a Q4 net loss of US$9.3 million and a full-year net loss of US$138.9 million on US$241.5 million in revenue, according to its latest FY 2025 earnings report. While Q4 saw a narrowed loss per share compared to earlier in the fiscal year, the company continues to face significant losses and slow revenue growth. This performance places current optimism about future profitability and a low P/S ratio against historical widening losses and risks like tightening data privacy rules and industry consolidation.
Massive goodwill hit but cash-positive quarter for Definitive Healthcare (DH)
Definitive Healthcare (DH) reported a Q1 2026 GAAP net loss of $192.4 million, significantly impacted by a $197.2 million goodwill impairment charge. Despite this, the company achieved positive non-GAAP profitability with Adjusted Net Income of $8.5 million and Adjusted EBITDA of $15.3 million, and generated $11.6 million in operating cash flow. Definitive Healthcare also provided 2026 full-year guidance expecting revenue between $220.0–$226.0 million and Adjusted EBITDA of $55.0–$59.0 million.
Definitive Healthcare posts $192M Q1 loss on $197M impairment
Definitive Healthcare (NASDAQ: DH) reported a Q1 2026 net loss of $(192.4) million, primarily due to a $197.2 million goodwill impairment charge, despite revenue falling 6% year-over-year to $55.9 million. The company achieved adjusted net income of $8.5 million and adjusted EBITDA of $15.3 million, demonstrating profitability on an adjusted basis and strong cash flow from operations. Definitive Healthcare also provided Q2 and full-year 2026 guidance, emphasizing continued focus on profitability and cash generation.
Definitive Healthcare (DH) CFO has shares withheld to cover RSU tax obligations
Definitive Healthcare Corp.'s CFO, Casey Heller, had 1,469 shares of Class A Common Stock withheld at $0.99 per share to satisfy tax obligations related to the vesting of previously reported Restricted Stock Units (RSUs) on May 1, 2026. This transaction was a non-market disposition for tax purposes, not a sale. Following this event, Heller directly holds 2,005,853 shares of Class A Common Stock.
Definitive Healthcare (DH) chair has 12,166 shares withheld for taxes
Definitive Healthcare's executive chairman, Jason Ronald Krantz, had 12,166 Class A common shares withheld at $0.99 per share to satisfy tax obligations related to the vesting of previously reported Restricted Stock Units (RSUs). This transaction was a tax withholding and not an open-market sale. Following this, Krantz directly holds 1,201,438 Class A shares and indirectly benefits from 450,000 shares held in the DH Holdings trust.
Definitive Healthcare to post Q1 results May 7, webcast at 5 p.m. ET
Definitive Healthcare (Nasdaq: DH) announced it will report its Q1 2026 financial results on Thursday, May 7, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET to discuss the results, with replay availability until June 6, 2026. This announcement sets the stage for investor focus on revenue, profitability, and updates to the 2026 guidance.
Definitive Healthcare (NASDAQ: DH) seeks 15M-share increase to equity plan in 2026 proxy
Definitive Healthcare (NASDAQ: DH) is seeking stockholder approval to increase its 2021 Equity Incentive Plan by 15 million shares, bringing the total to 45,972,789 shares. This proposal, part of its 2026 proxy statement, is intended to support future equity grants for employee, director, and consultant compensation. Other proposals include the election of three Class II directors, ratification of Deloitte & Touche LLP as the independent auditor for 2026, and an advisory vote on executive compensation.
Definitive Healthcare (NasdaqGS:DH) Stock Forecast & Analyst Predictions
Definitive Healthcare (DH) is forecast to achieve profitability within the next three years, with annual earnings expected to grow by 113.7% and EPS by 93.2% per year. Despite this, revenue is projected to decline at 2.6% annually, and its future return on equity is estimated at 2.5%. Recent analyst updates have led to revised price targets, reflecting factors such as lower fair value estimates, higher discount rates, and adjusted profit margin expectations.
DH SEC Filings - Definitive Healthcare Corp. 10-K, 10-Q, 8-K Forms
This page provides access to Definitive Healthcare (DH) SEC filings, including 10-K, 10-Q, 8-K, and insider trading reports, enhanced with AI-powered summaries and sentiment analysis. It features details on the company's operations, governance, and financial reporting, catering to investors and traders. The most recent filing discussed is an 8-K from July 1, 2025, and a Form 3 insider filing from June 18, 2025, noting the new Chief Legal Officer holds no DH shares.
Definitive Healthcare Corp. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Data
Definitive Healthcare Corp. (NASDAQ: DH) has filed a Form 8-K with the SEC announcing the termination of a material definitive agreement, specifically the Nominating Agreement, on April 3, 2026. This action could impact board composition and corporate governance, potentially leading to price sensitivity for its stock. Investors are advised to monitor future disclosures for further clarity on the long-term implications.
Definitive Healthcare Ends Spectrum Nomination Rights Agreement
Definitive Healthcare (DH) has officially ended its 2021 nominating agreement with private equity affiliate Spectrum, concluding Spectrum’s special board nomination rights. This follows the resignation of Spectrum designee Jeff Haywood from Definitive Healthcare’s board on March 30, 2026. The move simplifies the company's governance structure and is seen as a step away from private equity influence.
Definitive Healthcare ends nominating agreement with Spectrum following board resignation
Definitive Healthcare Corp. (NASDAQ:DH) has terminated its Nominating Agreement with SE VII DHC AIV, L.P. (Spectrum) following the resignation of Spectrum's designated director, Jeff Haywood, from the company's board. The agreement, which allowed Spectrum to nominate a board member if it held at least 5% of the common stock, was formally ended on April 3. This change follows recent financial results where Definitive Healthcare beat revenue expectations but missed on EPS, and saw a lowered price target from Stephens.
Definitive Healthcare ends nominating agreement with Spectrum following board resignation
Definitive Healthcare (NASDAQ:DH) has terminated its Nominating Agreement with SE VII DHC AIV, L.P., also known as Spectrum, following the resignation of Spectrum's designated board member, Jeff Haywood. This agreement had previously granted Spectrum the right to nominate a director if they held at least 5% of the company's outstanding common stock. The termination, effective April 3, 2026, irrevocably ends future nomination rights.
Spectrum board nomination rights end at Definitive Healthcare (DH)
Definitive Healthcare (DH) announced the termination of a Nominating Agreement with SE VII DHC AIV, L.P. (Spectrum) on April 3, 2026. This agreement, originally dated September 17, 2021, had granted Spectrum the right to designate one person for Definitive Healthcare's board slate as long as Spectrum beneficially owned at least 5% of the company's common stock. Jeff Haywood, the Spectrum Designee, resigned from the board on March 30, 2026, fully terminating the nomination rights.
Definitive Healthcare Corp. Files Form 8-K with SEC on March 30, 2026 – Company Details and Filing Information
Definitive Healthcare Corp. (NASDAQ: DH) has filed an 8-K form with the SEC on March 30, 2026, announcing the resignation of Jeff Haywood from its Board of Directors and the Human Capital Management and Compensation Committee. This change is considered significant for the company's corporate governance and investor confidence, though no immediate financial impact was disclosed. The company, incorporated in Delaware, operates in the Services-Prepackaged Software sector and is not classified as an emerging growth company.
Definitive Healthcare Corp. Announces Resignation of Jeff Haywood from Board and as Member of the Human Capital Management and Compensation Committee, Effective March 30, 2026
Definitive Healthcare Corp. announced the resignation of Jeff Haywood from its Board of Directors and the Human Capital Management and Compensation Committee, effective March 30, 2026. Following his resignation, the size of the Board was reduced from 9 to 8 members, and the Compensation Committee was reduced from 3 to 2 members. This change was publicly released on April 3, 2026.
Definitive Healthcare director Jeff Haywood resigns from board and committee By Investing.com
Jeff Haywood has resigned from Definitive Healthcare Corp.'s Board of Directors and the Human Capital Management and Compensation Committee, effective March 30, 2026. This resignation was not due to any disagreements with the company's operations or policies, and consequently, the Board and Compensation Committee sizes have been reduced. This news follows the company's Q4 fiscal 2025 earnings report, which showed mixed results, including exceeding revenue estimates but missing EPS predictions, leading Stephens to lower its price target.
Definitive Healthcare (DH) CEO has RSU shares withheld for taxes
Definitive Healthcare Corp.'s CEO, Kevin Coop, had 37,593 shares of Class A Common Stock withheld on April 1, 2026, to cover tax obligations stemming from RSU vesting. This was a tax-withholding disposition, not an open-market sale, and he now directly holds 5,078,872 shares. The event is considered neutral in terms of market impact and sentiment.
Definitive Healthcare (DH) chair has 45,154 shares withheld for RSU tax obligations
Jason Ronald Krantz, director and executive chairman of Definitive Healthcare Corp. (DH), had 45,154 shares of Class A Common Stock withheld on April 1, 2026, to cover tax obligations stemming from the vesting of Restricted Stock Units (RSUs). This was a tax-withholding disposition by the issuer, not an open-market sale, with the shares valued at $1.09 each. Following this transaction, Krantz directly holds 1,213,604 shares and beneficially owns an additional 450,000 shares through a trust.
Director Jeff Haywood exits Definitive Healthcare (DH) board, shrinking seats
Definitive Healthcare Corp. announced that director Jeff Haywood resigned from its Board of Directors and the Human Capital Management and Compensation Committee, effective March 30, 2026. This resignation was not due to any disagreements with the company's operations. As a result, the board size decreased from nine to eight members, and the Compensation Committee from three to two members, without immediate replacement.
Definitive Healthcare Corp. Hits New 52-Week Low at $1.37
Definitive Healthcare Corp. has reached a new 52-week low of $1.37, marking a significant 76.41% drop in its stock price over the past year. With a market capitalization of $214 million and a P/E ratio of 6.00, the company exhibits limited profitability and has underperformed the S&P 500. This decline reflects ongoing competitive challenges in the Software Products industry.
Definitive Healthcare (DH) price target decreased by 29.12% to 2.82
The article reports that Definitive Healthcare (DH) has had its price target decreased by 29.12% to $2.82. No further details are provided in the snippet.
Definitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of "Reduce" by Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Reduce" rating from ten analysts, with an average 12-month target price of $3.52. The stock opened at $1.19, trading significantly below analyst targets and its 200-day simple moving average. Despite the negative sentiment, institutional ownership is high at 98.67%, with firms like Goldman Sachs and AQR notably increasing their stakes.
Definitive Healthcare Corp. (DH) matches Q4 earnings estimates
The article states that Definitive Healthcare Corp. (DH) matched its Q4 earnings estimates. This indicates that the company performed as expected by analysts during the quarter.
Definitive Healthcare stock holds at Neutral as revenue declines persist By Investing.com
BTIG has maintained its Neutral rating on Definitive Healthcare Corp (NASDAQ:DH) following its Q4 fiscal 2025 earnings report. Despite revenue exceeding estimates, the company experienced a 1.2% year-over-year decline in revenue and a 12% decline in remaining performance obligations, with both total and Enterprise customers decreasing sequentially. Although the stock has suffered a significant plunge, InvestingPro analysis suggests it is undervalued and analysts project a return to profitability in 2026.
Tax-withholding share transfer by Definitive Healthcare (DH) CEO Coop
Definitive Healthcare Corp. CEO Kevin Coop had 175,524 Class A shares withheld by the company at $1.28 per share to cover tax withholding obligations related to the vesting and settlement of previously reported Restricted Stock Units (RSUs). This transaction, identified by transaction code F, was not an open-market sale but an administrative measure. Following this tax-related disposition, Coop directly holds 5,116,465 shares of Definitive Healthcare common stock, maintaining a significant stake in the company.
Zacks Research Downgrades Definitive Healthcare (NASDAQ:DH) to Strong Sell
Zacks Research has downgraded Definitive Healthcare (NASDAQ:DH) to a "strong sell" rating. This follows several other analysts' reports, resulting in an overall average rating of "Reduce" and a consensus price target of $3.52. The stock opened at $1.18, trading down 3.3%, with a market capitalization of $166.8 million and primarily institutional ownership.
Definitive Healthcare Corp. Hits New 52-Week Low at $1.14
Definitive Healthcare Corp. has reached a new 52-week low of USD 1.14, representing a 78.12% drop in one-year performance and a significant decline from its 52-week high of USD 4.70. With a market capitalization of USD 214 million, the company exhibits low profitability, a negative debt-to-equity ratio, and no dividend yield, suggesting financial instability and ongoing challenges in the market. Its performance consistently lags behind the S&P 500.
Definitive Healthcare Corp. Hits New 52-Week Low at $1.10
Definitive Healthcare Corp. has reached a new 52-week low of $1.10, with its stock price plummeting 80.51% over the past year. The company, a microcap player in the Software Products industry with a market capitalization of $214 million, displays low valuation metrics including a P/E ratio of 6.00 and a price-to-book ratio of 0.75. Its consistent underperformance against the S&P 500 signals significant financial struggles and a need for strategic reassessment.
Definitive Healthcare (NASDAQ:DH) Stock Rating Lowered by Wall Street Zen
Definitive Healthcare (NASDAQ:DH) has had its stock rating downgraded by Wall Street Zen from a "buy" to a "hold" due to lowered Q1 and full-year 2026 guidance, despite Q4 revenue being in line. The company's profitability metrics deteriorated year-over-year, and several institutional investors have trimmed their positions, indicating reduced confidence. The stock currently holds an average "Hold" rating with an average target price of $3.52 from analysts.
Canaccord Genuity Group Has Lowered Expectations for Definitive Healthcare (NASDAQ:DH) Stock Price
Canaccord Genuity Group has reduced its price target for Definitive Healthcare (NASDAQ:DH) from $4.00 to $3.00, maintaining a "hold" rating after the company lowered its Q1 and FY 2026 guidance. This news led to an 11.8% drop in shares to $1.24, despite some positive Q4 revenue and cash improvements. The consensus target price from analysts for DH is now $3.52, with institutional investors holding a significant portion of the stock.
Definitive Healthcare (DH) Quarterly Loss Highlights Ongoing Profitability Gap Despite Stable Revenue
Definitive Healthcare (DH) concluded FY 2025 with a Q4 revenue of US$61.5 million and a basic EPS loss of US$0.09, reflecting ongoing profitability challenges despite stable revenue figures. The company's net losses for the trailing twelve months reached US$138.9 million, significantly diverging from analyst expectations for future positive earnings. While the stock's low P/S ratio and discount to DCF fair value present a potential opportunity for long-term investors, the persistent losses and forecast revenue decline highlight significant risks.
Definitive Healthcare (DH) CEO granted 1.7M RSUs in new equity award
Definitive Healthcare Corp.'s CEO, Kevin Coop, has been granted 1,735,437 restricted stock units (RSUs) as a new equity award. These RSUs will vest over approximately three years, beginning with 25% on March 1, 2027, followed by quarterly vesting, contingent on his continued service. Following this grant, Coop beneficially owns 5,291,989 shares of Class A Common Stock.
Stephens Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $2.00
Stephens has lowered its price target for Definitive Healthcare (NASDAQ:DH) from $3.00 to $2.00, maintaining an "equal weight" rating, which still suggests a significant upside of 68% from its current share price. This adjustment comes amidst broader analyst sentiment reflecting a "Hold" rating for the stock, with an average target price of $3.66. The company's shares are currently trading near a one-year low, pressured by reduced Q1 and FY2026 guidance, GAAP losses, and weaker operating cash flow, despite some year-over-year cash improvement.
Definitive Healthcare (DH) CFO receives 733,301 RSU equity award in new grant
Definitive Healthcare Corp.'s CFO, Casey Heller, has been granted 733,301 restricted stock units (RSUs) of Class A common stock at $0.00 per share. These RSUs will vest 25% on March 1, 2027, with the remainder vesting in 6.25% increments every three months over the subsequent three years, contingent on Heller's continued employment. Following this award, Heller directly holds 2,007,322 shares or RSU-linked interests in the company.
[8-K] Definitive Healthcare Corp. Reports Material Event | DH SEC Filing - Form 8-K
Definitive Healthcare Corp. reported mixed financial results for Q4 and full year 2025, with revenue declines but improved profitability metrics and narrowed net losses. The company provided guidance for Q1 and full year 2026, anticipating further revenue decreases but maintaining focus on improving retention rates and increasing upsell/cross-sell activities. Despite ongoing goodwill impairments, Definitive Healthcare highlights solid underlying cash economics as it works towards better operational and financial performance.
Definitive Healthcare (NASDAQ: DH) chair awarded 242,719 RSUs vesting 2027
Definitive Healthcare (NASDAQ: DH) executive chairman and 10% owner Jason Ronald Krantz was granted 242,719 restricted stock units (RSUs) on February 24, 2026, as reported in a SEC Form 4 filing. These RSUs vest 100% on March 1, 2027, contingent on his continued service to the company. Following this grant, Krantz directly holds 1,258,758 shares and indirectly 450,000 shares through DH Holdings.
Definitive Healthcare (DH) EVP corrects Form 3, discloses 4,045.654 shares
Benjamin Graboske, EVP and Chief Data Officer of Definitive Healthcare Corp. (DH), has filed an amended Form 3 to correct his initial statement of beneficial ownership. The amendment discloses 4,045.654 shares of Class A Common Stock that were mistakenly omitted from his original Form 3 and two subsequent Form 4 filings. This filing clarifies his direct beneficial ownership of these shares and does not represent a new transaction.
Definitive Healthcare (DH) Earnings Transcript
Definitive Healthcare (DH) reported Q4 results that surpassed internal guidance for revenue and adjusted EBITDA, despite an overall 1% revenue decline year-over-year. The company restored claims data volumes and saw improvements in gross dollar retention, driven by enterprise accounts and growth in diversified and provider segments, though net dollar retention faced pressure from fewer upsell opportunities. Looking to 2026, the company forecasts continued revenue contraction but anticipates future improvement through product innovation, including GenAI integration, and ongoing strategic efforts to enhance customer retention and upsell capabilities.
Definitive Healthcare (DH) Earnings Transcript
Definitive Healthcare (DH) reported Q4 2025 financial results, exceeding revenue and adjusted EBITDA guidance despite a 1% year-over-year revenue decrease. The company successfully remediated industry-wide claims data disruptions, restored data volumes, and saw improvements in gross dollar retention, while net dollar retention declined due to fewer upsell opportunities. Looking ahead to 2026, the company anticipates continued revenue contraction but expects improvements in product innovation, especially with GenAI integration, and ongoing strategic investments to drive future growth and enhance customer retention.
Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of "Hold" by Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $3.94. The company's Q4 results showed stronger cash and steady revenue, but Q1 and FY-2026 EPS guidance fell below consensus estimates, leading to disappointment. Institutional selling in Q4 also contributed to near-term downward pressure on the stock, which trades near $1.40.
Definitive Healthcare (NASDAQ:DH) Updates FY 2026 Earnings Guidance
Definitive Healthcare (NASDAQ:DH) updated its FY 2026 earnings guidance, projecting EPS between $0.140 and $0.170 and revenue between $220.0 million and $226.0 million, both figures falling short of consensus analyst estimates. The company also set its Q1 2026 EPS guidance at $0.03. Following this announcement, the stock slipped to $1.40, trading near its 52-week low, while analysts maintain a consensus "Hold" rating with an average price target of $3.94 despite recent downgrades.
Definitive Healthcare (NASDAQ:DH) Releases Q1 2026 Earnings Guidance
Definitive Healthcare (NASDAQ:DH) has released its earnings guidance for Q1 2026 and updated its full-year 2026 outlook, projecting lower EPS and revenue than analyst consensus for the first quarter. Despite beating revenue estimates and meeting EPS for the most recent quarter, the company recorded a negative net margin of approximately -77.9%. Analysts currently rate the stock as "Hold" with a consensus target price of $3.94, while the stock trades near a 1-year low, and institutional investors hold a significant majority of its shares.
Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
Definitive Healthcare Corp. (DH) reported its Q4 2025 earnings, showing a revenue decline of 1.21% year-over-year to $61.5 million, which slightly beat estimates. However, the company missed EPS estimates with a diluted EPS of -$0.09, leading to a 2.99% stock drop. Insider trading data shows significant institutional selling, with 53 institutions adding shares and 96 decreasing positions, while analysts have set a median price target of $3.375.
Healthcare data firm Definitive narrows Q4 net loss to $17.1M
Definitive Healthcare (NASDAQ: DH) reported its Q4 and full fiscal year 2025 financial results, with fourth-quarter revenue hitting $61.5 million and full-year revenue reaching $241.5 million. The company narrowed its Q4 net loss to $(17.1) million, significantly improving from $(84.7) million in Q4 2024, despite a full-year net loss of $(199.3) million largely due to goodwill impairments. Definitive Healthcare also provided guidance for fiscal year 2026, projecting revenue between $220.0 million and $226.0 million and adjusted EBITDA between $53.0 million and $58.0 million.
Large RSU grant to Definitive Healthcare (DH) Chief Legal Officer disclosed
Definitive Healthcare Corp. (DH) Chief Legal Officer Jonathan Paris was granted 481,505 restricted stock units (RSUs). These RSUs, which represent shares of Class A common stock, will vest 25% on March 1, 2027, and then 6.25% every three months over the subsequent three years, contingent on his continued employment. This transaction was disclosed in a Form 4 SEC filing on February 26, 2026, and increases his beneficial ownership to 902,854 shares.
Definitive Healthcare Corp. (NASDAQ:DH) Not Doing Enough For Some Investors As Its Shares Slump 26%
Definitive Healthcare Corp. (NASDAQ:DH) has seen its shares drop significantly, with a 26% decline in the last month and a 65% drop over the past year. Its low price-to-sales (P/S) ratio of 0.8x, compared to an industry average of 2.1x, reflects declining revenues and a negative growth outlook. Analysts forecast a 3.0% revenue decrease for the company while the industry is expected to grow by 12%, justifying the current low valuation but signaling potential difficulties for share price recovery.
Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Rating of "Hold" from Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $3.94. The company recently beat its earnings and revenue estimates but still posted a negative net margin of 77.88%. Institutional investors hold approximately 98.67% of the company's stock, which currently trades around $2.32.
